FDA 483 - Natren, Inc. - November 02, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Natren, Inc. in Westlake Village, CA, a manufacturer of homeopathic drug products, revealed significant deficiencies in quality control and manufacturing practices. Observations included failures in testing and releasing components before use, lack of a written stability assessment program for drug products, and an inadequately defined and independent quality control unit. These issues raise concerns about the quality, safety, and efficacy of the firm's homeopathic products.
ID · f982f1c7-0e73-405d-8f17-ac20111cd61c